Haemostatic aspects in clinical oncology;Hämostaseologische aspekte in der onkologie

Hamostaseologie

Volumn 28, Issue 5, 2008, Pages 472-480

  Langer, Florian ^a   Holstein, K ^a   Eifrig, B ^a   Bokemeyer, C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cancer; Low molecular weight heparin; Tissue factor; Trousseau's syndrome

Indexed keywords

DALTEPARIN; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN;

BLOOD CLOTTING DISORDER; CANCER GROWTH; CARCINOGENESIS; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; GENE MUTATION; GENETICS; HEMOSTASIS; HUMAN; METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; ONCOLOGY; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; THROMBOCYTE; THROMBOSIS; THROMBOSIS PREVENTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VENOUS THROMBOEMBOLISM;

HEMOSTASIS; HEMOSTATIC DISORDERS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; THROMBOPLASTIN; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 58149457268     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Abdulkadir SA, Carvalhal GF, Kaleem Z et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443-447.
2. Abe K, Shoji M, Chen J, Bierhaus A et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 8663-8668.
3. Ahamed J, Versteeg HH, Kerver M et al. Disulfide isomerization switches tissue factor from coagulation to cell signalling. Proc Natl Acad Sci USA 2006; 103: 13932-13927.
4. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003; 62: 1078-1082.
5. Altinbas M, Coskun HS, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-1271.
6. Amarzguioui M, Peng Q, Wiiger MT et al. Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 2006; 12: 4055-4061.
7. Belting M, Dorrell MI, Sandgren S et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 502-509.
8. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25: 1545-1550.
9. Boccaccio C, Sabatino G, Medico E et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434: 396-400.
10. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97: 3044-3052.
11. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl 1): 246-254.
12. Camerer E, Qazi AA, Duong DN et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
13. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-215.
14. De la Fouchardière C, Flechon A, Droz JP. Coagulopathy in prostate cancer. Neth J Med 2003; 61: 347-354.
15. Del Conde I, Bharwani LD, Dietzen DJ et al. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5: 70-74.
16. Dirix LY, Salgado R, Weytjens R et al. Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395.
17. Falanga A. Biological and clinical aspects of anticancer effects of antithrombotics. Pathophysiol Haemost Thromb 2003/2004; 33: 389-392.
18. Franis JL, Amirkhosravi A. Effect of hemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002; 28: 29-38.
19. Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992; 6: 1301-1314.
20. Gupta GP, Massagué J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004; 114: 1691-1693.
21. Han LY, Landen CN Jr, Kamat AA et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
22. Hron G, Kollars M, Weber H et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
23. Hull RD, Pineo GF, Brant RF et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
24. Im JH, Fu W, Wang H et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004; 64: 8613-8619.
25. Kakkar AK, Lemoine NR, Scully MF et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
26. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
27. Kakkar AK. Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control 2005; 12: 22-30.
28. Karthaus M, Kretzschmar A, Kröning H et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 289-296.
29. Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.
30. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Haemost 2003; 29: 301-308.
31. Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79: 19-22.
32. Langer F, Steinmetz O, Marx G et al. Aprotinin-associated hemolytic thrombotic microangiopathy in a patient with acute myelogenous leukemia (AML) and systemic coagulopathy. Am J Hematol 2007; 82: 1122-1124.
33. Langer F, Spath B, Haubold K et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008; 87: 451-457.
34. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
35. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: 117-121.
36. Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128: 291-302.
37. Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2139.
38. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 2003; 1: 1456-1463.
39. Levine M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question. J Thromb Haemost 2006; 4: 16-18.
40. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.
41. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular- heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
42. Ohta S, Wada H, Nakazaki T et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-2996.
43. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31: 388-394.
44. Palumbo JS, Kombrinck KW, Drew AF et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-3309.
45. Palumbo JS, Talmage KE, Massari JV et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
46. Palumbo JS, Talmage KE, Massari JV et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood 2007; 110: 133-141.
47. Piccioli A, Lensing AW, Prins MH et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 884-889.
48. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410.
49. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66: 10643-10646.
50. Rickles FR, Patierno S, Fernandez EM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58s-68s.
51. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006; 35: 103-110.
52. Rong Y, Post DE, Pieper RO et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 1406-1413.
53. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32: 61-68.
54. Seitz R, Rappe N, Kraus M et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 1993; 4: 249-254.
55. Shigemori C, Wada H, Matsumoto K et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894-898.
56. Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007; 33: 330-338.
57. Tesselaar ME, Romijn FP, van Der Linden IK et al. Microparticle- associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-527.
58. Trousseau A. Phlegmasia alba dolens. In: Clinique medicinale de l'Hotel-Dieu de Paris. Paris: Bailliere J.-B. et fils 1865: 645-712.
59. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-1729.
60. Verso M, Agnelli G, Bertoglio S et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-4062.
61. Versteeg HH, Schaffner F, Kerver M et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190-199.
62. Yu JL, May L, Lhotak V et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-1741.
63. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. The oncologist 2005; 10: 72-79.
64. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007; 33: 339-349.